Introduction

This report provides comprehensive coverage of the diabetes market, incorporating a disease overview and detailed epidemiological analyses of the therapy area. It makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market-share data, sales forecasts and competitive landscape of the major players. The market size is forecast to 2016.

Features and benefits

* Quantify and assess the patient potential and treatment trends of diabetes globally.
* Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges.
* Benchmark the leading anti-diabetic pipeline products under development and evaluate the evolution of the market in the forecast period.
* Identify the leading players in the diabetes market and analyze their marketed portfolios, R&D pipelines and market strategies.
* Evaluate the key market trends and growth strategies that holds potential for shaping the future diabetes market.

Highlights

Diabetes is the fifth leading cause of death in the developed countries. Diabetes prevalence is increasing at a fast pace in the developing countries due to lifestyle changes and a lack of awareness of its causes. This presents a huge opportunity to the marketers of diabetes products.
The diabetes landscape is dynamic, with active R&D leading to the development of newer drug classes such as incretin mimetics, and regulatory agencies such as the FDA having increased the regulatory surveillance over diabetes drugs to avoid any “unacceptable” cardiovascular risk.
Stringent regulatory screening in the light of increasing reports of serious adverse events of cardiovascular risk factors has had repercussions in terms of product withdrawal and has also delayed the launch of several late stage development products.

Your key questions answered

* What are the new therapy approaches in anti-diabetes market and which of these offer significant potential in the future?
* What is the forecast commercial potential of the most promising compounds in clinical development?
* Which products have been the major revenue generators in the market and what other categories are forecast to have commercial potential through 2016?
* What are the current growth drivers in the global diabetes market shaping the future?
* How will the patient population of diabetes sufferers change between 2010 and 2016?

Executive Summary
Overview and patient potential of diabetes
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and patient potential of diabetes
Summary
Introduction
What is diabetes?
Types of diabetes
Type 2 diabetes
Gestational diabetes mellitus
Impaired glucose tolerance
Diabetic complications
Epidemiology
Diagnosis
How is diabetes measured?
Treatment algorithm
Global market analysis
Summary
Introduction
Market analysis by country
India
China
Key events/trends in the diabetes market
Bydureon approved in the EU
Eli Lilly and Boehringer Ingelheim’s collaborates over diabetes drug
Novo Nordisk receives subpoena for three marketed products
Newer agents recommended by NICE for diabetes treatment
Amylin sues Lilly
Market analysis by drug class
Diabetes drug classes
The insulin landscape
Drugs targeting underlying causes of diabetes
DPP-IV and GLP-1 differences
Therapy area sales forecast
Leading brands of the diabetes market
Leading brands sales forecast
Pipeline analysis
Summary
Introduction
Emerging trends/key events in diabetes R&D
Unmet need
Inhaled insulin still a distant reality
New approaches in diabetes R&D: magnesium, chromium, and vanadium
Regulatory changes in the light of increasing cardiovascular adverse effects
Profiles of key pipeline products
Profiles of key molecules
Pipeline sales forecast
Competitive Landscape
Summary
Introduction
Detailed analysis of the diabetes market players
Novo Nordisk
Sanofi
Takeda
Eli Lilly
Merck & Co.
Appendix
Scope
Market forecast
Epidemiology forecast
Glossary/Abbreviations
Bibliography/References